An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
- Status
- COMPLETED
- Phase
- PHASE3
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant and Adjuvant Checkpoint Blockade
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Cytokine-induced Killer Study for Patients With Stage II Melanoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3